Home › NCT05302583
Aromatherapy Inhaler Use for HSCT Distress
Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Autologous and Allogeneic patients admitted to E1 for planned HSCT * Patients with hematologic malignancies requiring HSCT * No allergies to lavender or peppermint essential oils * Must have received chemotherapy during preparative regimen (single or multi-agent regimen) * Adult patient over 18 years of age * Able to speak, read, and comprehend English * Willing and capable of providing informed consent Exclusion Criteria: * Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion * Patients receiving a transplant for a germ cell tumor diagnosis * Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration) * Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4 * History of scleroderma * History of atrial fibrillation * Known history of G6PD deficiency * Allergic to lavender or peppermint essential oils * Pediatric patient 18 years of age or less * Unable to speak, read, and comprehend English * Unwilling or incapable of providing informed consent
About the study
This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.
What is being tested
- Aromatherapy Stick (other)
- Standard of Care (other)
Sponsor: Stanford University · Participants: 50 · Started: Jun 16, 2025
Contact the study team
- Anna Oh, PhD, MPH, RN · Phone: 650-512-6691
Official record on ClinicalTrials.gov — NCT05302583
Locations in the U.S.
| California | Stanford University, Stanford |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.